Drug Trial Radar · NCT04641442
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Dec 18, 2020
Primary completion
Oct 14, 2025
Study completion Nov 23, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Conditions
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Interventions
MAS825Biological
Experimental drug
PlaceboBiological
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Occurrence of disease flare in patients with MAS825 treated patients compared with placebo during Period 2 assessed by Physician's Global Assessment and inflammatory markersTime frame: Period 2 (during the randomized, placebo-controlled period of up to 6 months)
Locations
12 sites in 7 countries. Site status is shown where the registry gives one.
Cincinnati Children's Hospital
Cincinnati, Ohio
Children´s Hospital of Philadelphia
Philadelphia, Pennsylvania
Texas Children´s Hospital
Houston, Texas
Seattle Children´s Hospital
Seattle, Washington
Ustav Imunologie 2 LF UK a FN Motol
Prague, Czechia
Centrum detske revmatologie a autoinflamatornich onemocneni
Prague, CZ, Czechia
Novartis Investigative Site
Paris, France
Bambino Gesu Hospital
Roma, RM, Italy
Novartis Investigative Site
Chiba, Japan
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
London, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.